SG10201805207QA - Factor viii polypeptide formulations - Google Patents

Factor viii polypeptide formulations

Info

Publication number
SG10201805207QA
SG10201805207QA SG10201805207QA SG10201805207QA SG10201805207QA SG 10201805207Q A SG10201805207Q A SG 10201805207QA SG 10201805207Q A SG10201805207Q A SG 10201805207QA SG 10201805207Q A SG10201805207Q A SG 10201805207QA SG 10201805207Q A SG10201805207Q A SG 10201805207QA
Authority
SG
Singapore
Prior art keywords
factor viii
fviii
viii polypeptide
polypeptide
polypeptide formulations
Prior art date
Application number
SG10201805207QA
Inventor
Kevin Maloney
Ahmad Abdul-Fattah
Daniel Gage
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201805207Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of SG10201805207QA publication Critical patent/SG10201805207QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

FACTOR VIII POLYPEPTIDE FORMULATIONS The present invention provides a formulation of a Factor VIII polypeptide, e.g., FVIII-Fc, and methods of using the same. The FVIII polypeptide can be a recombinant FVIII protein, a short-acting FVIII protein, or a long-acting FVIII protein. The pharmaceutical formulation comprising a FVIII polypeptide can be used for individual prophylaxis, weekly prophylaxis, episodic (on-demand) treatment, or perioperative management of hemophilia. No suitable Fig.
SG10201805207QA 2013-03-15 2014-03-14 Factor viii polypeptide formulations SG10201805207QA (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361800293P 2013-03-15 2013-03-15
US201361817085P 2013-04-29 2013-04-29
US201361829884P 2013-05-31 2013-05-31
US201361839477P 2013-06-26 2013-06-26
US201361863860P 2013-08-08 2013-08-08
US201361876927P 2013-09-12 2013-09-12
US201361879955P 2013-09-19 2013-09-19
US201361897742P 2013-10-30 2013-10-30

Publications (1)

Publication Number Publication Date
SG10201805207QA true SG10201805207QA (en) 2018-07-30

Family

ID=50771579

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201805207QA SG10201805207QA (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations
SG11201505924TA SG11201505924TA (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201505924TA SG11201505924TA (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations

Country Status (21)

Country Link
US (3) US9623088B2 (en)
EP (3) EP4122487A1 (en)
JP (5) JP6330026B2 (en)
AU (3) AU2014228506A1 (en)
CA (1) CA2899737A1 (en)
CL (1) CL2015002720A1 (en)
DK (1) DK2968477T3 (en)
EA (2) EA201890671A1 (en)
ES (2) ES2776195T3 (en)
HK (1) HK1220617A1 (en)
HU (1) HUE047933T2 (en)
LT (1) LT2968477T (en)
PH (2) PH12015501801B1 (en)
PL (2) PL2968477T3 (en)
PT (2) PT3666283T (en)
RS (1) RS60003B1 (en)
SG (2) SG10201805207QA (en)
SI (1) SI2968477T1 (en)
TW (2) TWI629993B (en)
UY (1) UY35462A (en)
WO (1) WO2014144795A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2880038T3 (en) * 2009-12-06 2021-11-23 Bioverativ Therapeutics Inc Chimeric and Hybrid Factor VIII-Fc Polypeptides and Methods of Using The Same
AU2014228938B2 (en) 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
LT2968477T (en) * 2013-03-15 2020-03-10 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
CN106279437B (en) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes
CN107759694B (en) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 Bispecific antibody, preparation method and application thereof
BR112019011115A2 (en) 2016-12-02 2019-10-01 Bioverativ Therapeutics Inc methods for treating hemophilic arthropathy using chimeric clotting factors
BR112019011198A2 (en) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc methods of inducing immune tolerance to coagulation factors
JP7039308B2 (en) * 2017-02-08 2022-03-22 三洋化成工業株式会社 Cell culture carrier
TW201920255A (en) 2017-08-09 2019-06-01 美商生物化學醫療公司 Nucleic acid molecules and uses thereof
AU2018366110A1 (en) 2017-11-07 2020-06-04 Rani Therapeutics, Llc Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
JP2021523878A (en) 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド How to treat hemophilia A
BR112021002017A2 (en) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. nucleic acid molecules and their uses for non-viral gene therapy
AU2019366942A1 (en) * 2018-10-23 2021-06-10 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor VIII function
EP3932486A4 (en) * 2019-02-28 2022-11-30 Public University Corporation Yokohama City University Composition for treating blood coagulation and/or complement disorders
KR20220009389A (en) 2019-04-17 2022-01-24 코디악 바이오사이언시즈, 인크. Composition of exosomes and AAV
TW202115127A (en) 2019-06-19 2021-04-16 美商百歐維拉提夫治療公司 Methods and compositions for treating hemophilia and low bone mineral density
KR20230159284A (en) * 2022-05-10 2023-11-21 주식회사 녹십자 A Novel Liquid Formulation for Plasma Protein
KR20230159285A (en) * 2022-05-10 2023-11-21 주식회사 녹십자 A Novel Liquid Formulation for Lyophilization of Plasma Protein

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
KR910006424B1 (en) 1985-08-21 1991-08-24 인코텍스 비.브이 Method of manufacturing knitted briefs
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (en) 1987-06-19 1988-12-29 Behringwerke Ag FACTOR VIII: C-LIKE MOLECULE WITH COAGULATION ACTIVITY
FR2619314B1 (en) 1987-08-11 1990-06-15 Transgene Sa FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
EP0461200B1 (en) 1989-02-21 1997-01-22 Washington University Modified forms of reproductive hormones
SE465222C5 (en) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab A recombinant human factor VIII derivative and process for its preparation
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
JP3693671B2 (en) 1991-03-15 2005-09-07 アムゲン インコーポレーテッド PEGylation of polypeptides
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
DK0627924T3 (en) 1992-10-02 2001-04-30 Genetics Inst Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (en) 1993-07-05 1996-11-04 Pharmacia Ab Protein preparation for subcutaneous, intramuscular or intradermal administration
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9503380D0 (en) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
BR0008405B1 (en) * 1999-02-22 2014-04-22 Baxter Int FACTOR VIII COMPOSITION FORMULATED WITHOUT ADDED ALBUMIN, USE OF A FACTOR VIII COMPOSITION, AND METHOD OF LYOPHILIZING A WATER PHARMACEUTICAL FORMULATION
ES2269366T3 (en) 2000-02-11 2007-04-01 Merck Patent Gmbh IMPROVEMENT OF AVERAGE LIFE IN CIRCULATION OF FUSION PROTEINS BASED ON ANTIBODIES.
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP2298347B1 (en) 2003-05-06 2015-09-30 Biogen Hemophilia Inc. Clotting factor chimeric proteins for treatment of a hemostatic disorder
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
RU2373953C2 (en) * 2003-12-19 2009-11-27 Ново Нордиск Хелс Кеа Аг Stabilised composition, containing factor vii polypeptide
WO2006053299A2 (en) 2004-11-12 2006-05-18 Bayer Healthcare Llc Site-directed modification of fviii
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
KR20080098504A (en) 2006-02-03 2008-11-10 메디뮨 엘엘씨 Protein formulations
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
SI2173890T1 (en) 2007-06-21 2011-06-30 Univ Muenchen Tech Biological active proteins having increased in vivo and/or vitro stability
US8239182B2 (en) 2007-12-04 2012-08-07 Spansion Llc Data transmission system-on-chip memory model based validation
JP5647899B2 (en) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ Glycoconjugation of polypeptides using oligosaccharyltransferase
EP2417155B1 (en) * 2009-04-06 2013-06-19 Novo Nordisk A/S Targeted delivery of factor viii proteins to platelets
ES2880038T3 (en) 2009-12-06 2021-11-23 Bioverativ Therapeutics Inc Chimeric and Hybrid Factor VIII-Fc Polypeptides and Methods of Using The Same
RS58578B1 (en) 2011-07-08 2019-05-31 Bioverativ Therapeutics Inc Factor viii chimeric and hybrid polypeptides, and methods of use thereof
CA2850579A1 (en) * 2011-10-18 2013-04-25 Carsten Horn Method for improving the stability of purified factor viii after reconstitution
US20160000884A1 (en) * 2012-08-13 2016-01-07 Novo Nordisk A/S Liquid Factor VIII Formulations
WO2014070953A1 (en) * 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
LT2968477T (en) * 2013-03-15 2020-03-10 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations

Also Published As

Publication number Publication date
PH12015501801A1 (en) 2015-11-09
SG11201505924TA (en) 2015-09-29
TWI690325B (en) 2020-04-11
JP6330026B2 (en) 2018-05-23
PH12019502452A1 (en) 2021-02-08
PL2968477T3 (en) 2020-06-15
AU2021277601A1 (en) 2021-12-23
AU2019202656A1 (en) 2019-05-09
AU2019202656B2 (en) 2021-09-02
HUE047933T2 (en) 2020-05-28
EP2968477A1 (en) 2016-01-20
PL3666283T3 (en) 2022-10-03
ES2776195T3 (en) 2020-07-29
WO2014144795A1 (en) 2014-09-18
SI2968477T1 (en) 2020-04-30
US20170281734A1 (en) 2017-10-05
EP2968477B1 (en) 2019-12-04
ES2926798T3 (en) 2022-10-28
LT2968477T (en) 2020-03-10
TW201501722A (en) 2015-01-16
HK1220617A1 (en) 2017-05-12
EA201890671A1 (en) 2019-01-31
JP6934994B2 (en) 2021-09-15
EA201591439A1 (en) 2016-03-31
EP3666283A1 (en) 2020-06-17
PT2968477T (en) 2020-03-11
JP2021181491A (en) 2021-11-25
EP4122487A1 (en) 2023-01-25
EA030357B1 (en) 2018-07-31
PT3666283T (en) 2022-09-13
TW201842930A (en) 2018-12-16
DK2968477T3 (en) 2020-03-09
UY35462A (en) 2014-10-31
US10786554B2 (en) 2020-09-29
US20140308280A1 (en) 2014-10-16
JP2016516722A (en) 2016-06-09
JP2020186268A (en) 2020-11-19
US9623088B2 (en) 2017-04-18
JP2018123161A (en) 2018-08-09
RS60003B1 (en) 2020-04-30
US20210069300A1 (en) 2021-03-11
PH12015501801B1 (en) 2015-11-09
AU2014228506A1 (en) 2015-08-13
EP3666283B1 (en) 2022-06-08
TWI629993B (en) 2018-07-21
CL2015002720A1 (en) 2016-11-04
JP7240457B2 (en) 2023-03-15
JP2023060146A (en) 2023-04-27
CA2899737A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
PH12019502452A1 (en) Factor viii polypeptide formulations
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
MX2021005907A (en) Liquid protein formulations containing ionic liquids.
PH12017500042A1 (en) Interleukin-2/interleukin-2-receptor alpha fusion proteins and methods of use
MX2019003716A (en) Pharmaceutical formulations of tnf-alpha antibodies.
EP3341400A4 (en) Cell-permeable bone morphogenetic protein (cp-bmp) recombinant protein and use thereof
EA201591752A1 (en) DIPEPTIDE AND TRIPEPTID EPOXYETONIC PROTEASE INHIBITORS
IL262568A (en) Protein based excipient for active pharmaceutical ingredients
MX2017003121A (en) Antibody formulations.
EP3334756A4 (en) Improved cell-permeable cre (icp-cre) recombinant protein and use thereof
TW201613557A (en) Stable aqueous recombinant protein formulations
EP3476937A4 (en) Chimera protein comprising fviii and vwf factors, and use thereof
EP3362048A4 (en) Composition for intraoral delivery of biologically active peptides and proteins
MX367858B (en) Conotoxin peptides, pharmaceutical compositions and uses thereof.
MX2013012337A (en) Compositions and methods.
SG10201803999UA (en) Recombinant factor viii formulations
MX2021003908A (en) Long-acting polypeptides and methods of producing and administering same.
AR122764A2 (en) FORMULATION OF A FACTOR VIII POLYPEPTIDE, PHARMACEUTICAL KIT, METHOD
EP3416677A4 (en) Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
EP3334755A4 (en) Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof
MX2016008170A (en) Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof.
IL283229A (en) High concentration protein formulation
IN2014MU00077A (en)
AR095431A1 (en) FORMULATIONS OF FVIII RECOMBINANT